瑞典AlzeCure Pharma公司在马德里CTAD会议上展示了ACD856的阿尔茨海默氏病改变潜力。 Swedish company AlzeCure Pharma presents ACD856's potential to modify Alzheimer's disease at CTAD Madrid conference.

瑞典一家侧重于神经系统疾病的AlzeCure Pharma公司宣布,将在马德里的CTAD会议上介绍该公司关于ACD856的抗炎和免疫瘤效应的摘要。 AlzeCure Pharma, a Swedish company focused on nervous system diseases, announced that its abstract on ACD856's anti-inflammatory and immunomodulatory effects will be presented at the CTAD conference in Madrid. 新的临床初步结果表明,ACD856可能具有阿兹海默氏病的疾病改变潜力。 New preclinical results suggest ACD856 may have disease-modifying potential for Alzheimer's. 首席执行官Martin Jönsson对在会上分享这些大有希望的结论表示满意。 CEO Martin Jönsson expressed satisfaction in sharing these promising findings at the conference.